ATE549343T1 - Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol - Google Patents

Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol

Info

Publication number
ATE549343T1
ATE549343T1 AT06755275T AT06755275T ATE549343T1 AT E549343 T1 ATE549343 T1 AT E549343T1 AT 06755275 T AT06755275 T AT 06755275T AT 06755275 T AT06755275 T AT 06755275T AT E549343 T1 ATE549343 T1 AT E549343T1
Authority
AT
Austria
Prior art keywords
alpha
dimethylamino
ethylü
meth
bromine
Prior art date
Application number
AT06755275T
Other languages
English (en)
Inventor
Frank Porstmann
Stefan Horns
Thomas Bader
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE549343T1 publication Critical patent/ATE549343T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
AT06755275T 2005-05-25 2006-05-22 Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol ATE549343T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05104482 2005-05-25
PCT/EP2006/062502 WO2006125769A1 (en) 2005-05-25 2006-05-22 Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
ATE549343T1 true ATE549343T1 (de) 2012-03-15

Family

ID=36013279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755275T ATE549343T1 (de) 2005-05-25 2006-05-22 Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol

Country Status (27)

Country Link
US (2) US8039628B2 (de)
EP (1) EP1888604B1 (de)
JP (1) JP5410749B2 (de)
KR (2) KR101712835B1 (de)
CN (1) CN101180302B (de)
AT (1) ATE549343T1 (de)
AU (1) AU2006251208B2 (de)
BR (1) BRPI0611166B1 (de)
CA (1) CA2606675C (de)
CY (1) CY1113383T1 (de)
DK (1) DK1888604T3 (de)
EA (1) EA011770B1 (de)
ES (1) ES2383908T3 (de)
HR (1) HRP20120429T1 (de)
IL (1) IL186913A (de)
ME (1) ME01445B (de)
MX (1) MX2007014874A (de)
NO (1) NO341633B1 (de)
NZ (1) NZ563819A (de)
PL (1) PL1888604T3 (de)
PT (1) PT1888604E (de)
RS (1) RS52316B (de)
SG (1) SG162724A1 (de)
SI (1) SI1888604T1 (de)
UA (1) UA92484C2 (de)
WO (1) WO2006125769A1 (de)
ZA (1) ZA200710150B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2668715B2 (ja) 1988-10-21 1997-10-27 住友重機械工業株式会社 コイル集束装置における切断制御法
EP1835115B1 (de) 2006-03-17 2013-05-29 Peter Villiger Schutzverfahren und Schutzsystem für Wertsachen
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
AU2016212116B2 (en) * 2015-01-27 2021-07-15 Janssen Pharmaceutica Nv Dispersible compositions
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CN107848978B (zh) * 2015-07-24 2021-04-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
AU2017229128B2 (en) 2016-03-07 2022-04-07 Janssen Pharmaceutica Nv Antibacterial compounds and uses thereof
CN107602464B (zh) * 2016-07-12 2020-02-18 宜昌人福药业有限责任公司 利用光学拆分制备双芳基喹啉类抗生素的方法
CN106866525B (zh) * 2017-03-24 2019-04-19 福建省微生物研究所 用于合成(1r,2s)-贝达喹啉的手性诱导剂
US11141384B2 (en) 2017-07-14 2021-10-12 Janssen Pharmaceutica Nv Long-acting formulations
CN109422679B (zh) * 2017-08-30 2021-06-25 武汉武药科技有限公司 一种贝达喹啉的纯化及稳定晶型的制备方法
CN107857727B (zh) * 2017-10-26 2019-10-18 江苏天和制药有限公司 一种（1r，2s）和（1s，2r）-贝达喹啉的制备方法
CN110759885B (zh) * 2018-07-27 2021-10-22 中国医学科学院药物研究所 制备光活依格鲁特的方法
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
US20230355606A1 (en) 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
JP2025532272A (ja) 2022-09-28 2025-09-29 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型製剤
JP7728461B1 (ja) 2023-08-01 2025-08-22 上海交通大学 低温で連続フローによりベダキリンを調製する方法及びこの方法により調製された製品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111138A1 (en) * 1993-01-15 1994-07-16 Thierry Godel Octahydrophenanthrene derivatives
US5319084A (en) * 1993-08-16 1994-06-07 Research Triangle Institute Hexahydroindenopyridine compounds having antispermatogenic activity
ES2343458T3 (es) * 2002-07-25 2010-08-02 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores de micobacterias.
WO2004060889A1 (en) 2003-01-07 2004-07-22 Glaxo Group Limited 5-thiazole substituted 2-pyrrolidine-carboxylic acids

Also Published As

Publication number Publication date
SG162724A1 (en) 2010-07-29
HRP20120429T1 (hr) 2012-06-30
WO2006125769A1 (en) 2006-11-30
PT1888604E (pt) 2012-05-28
KR20080010453A (ko) 2008-01-30
SI1888604T1 (sl) 2012-08-31
JP5410749B2 (ja) 2014-02-05
IL186913A (en) 2013-12-31
CY1113383T1 (el) 2016-06-22
US8039628B2 (en) 2011-10-18
IL186913A0 (en) 2008-02-09
EP1888604B1 (de) 2012-03-14
EA011770B1 (ru) 2009-06-30
HK1118061A1 (en) 2009-01-30
BRPI0611166A2 (pt) 2010-08-17
KR101534021B1 (ko) 2015-07-06
DK1888604T3 (da) 2012-06-18
ZA200710150B (en) 2012-06-27
RS52316B (sr) 2012-12-31
BRPI0611166B1 (pt) 2022-01-25
US20080200683A1 (en) 2008-08-21
CA2606675A1 (en) 2006-11-30
NZ563819A (en) 2011-01-28
PL1888604T3 (pl) 2012-08-31
EA200702611A1 (ru) 2008-04-28
CN101180302A (zh) 2008-05-14
CN101180302B (zh) 2013-06-19
JP2008545675A (ja) 2008-12-18
AU2006251208B2 (en) 2012-11-29
ME01445B (me) 2013-12-20
US8350040B2 (en) 2013-01-08
UA92484C2 (en) 2010-11-10
ES2383908T3 (es) 2012-06-27
KR20150008196A (ko) 2015-01-21
NO20076542L (no) 2007-12-19
AU2006251208A1 (en) 2006-11-30
NO341633B1 (no) 2017-12-11
EP1888604A1 (de) 2008-02-20
MX2007014874A (es) 2008-02-15
KR101712835B1 (ko) 2017-03-07
CA2606675C (en) 2013-02-19
US20110319623A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
ATE549343T1 (de) Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol
ATE486844T1 (de) Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien
DE602004014910D1 (de) Verfahren zur herstellung von derivaten chiraler beta-aminosäuren durch assymetrische hydrierung
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE443038T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
ATE544754T1 (de) Verfahren zur herstellung von ivabradinhydrochlorid
ATE539054T1 (de) Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE486857T1 (de) Verfahren zur herstellung von telmisartan
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
DE602006021411D1 (de) Verfahren zur herstellung von optional 2-substituierten 1,6-dihydro-6-oxo-4-pyrimidincarboxylsäuren
GT200400248A (es) Proceso para la preparacion de inhibidores de tubulina
ATE514702T1 (de) Verfahren zur herstellung von clopidogrel und dabei verwendete zwischenprodukte
ATE370950T1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
ATE388949T1 (de) Verfahren zur herstellung von z-flupentixol
ATE466010T1 (de) Verfahren zur herstellung von candesartan
ATE515502T1 (de) Verfahren zur herstellung von tetranorlabdanderivaten
ATE549315T1 (de) Verfahren zur herstellung von kristallinem perindopril
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
ATE349418T1 (de) Verfahren zur herstellung von nateglinidin der b- form
DE50203388D1 (de) Verbessertes verfahren zur herstellung von bisphosphiten
ATE354614T1 (de) Verfahren zur herstellung eines gehinderten aminlichtstabilisatorensalzes
DE502005008101D1 (de) Verfahren zur herstellung von carbodiimidgruppen aufweisenden substanzen